Easix as a predictor of severe infectious complications in AML patients that undergo intensive chemotherapy: a prospective multicenter cohort study

Abstract

BACKGROUND Infections are the most frequent complication and the first cause of mortality in AML intensive chemotherapy. Even though patients are closely monitored and treated for their infections, infection related mortality is still significant. The Endothelial Activation and Stress Index ( EASIX score LDH × creatinine /platelet count) was first developed to predict overall survival in complications related to allogenic hematopoietic transplants. Since then, several studies assessed the EASIX score prediction ability in different diseases, such as, ICANS and CRS in CAR T therapy, Multiple Myeloma, diffuse large B cell Lymphoma, COVID 19, sepsis, etc. To this date, there is no evidence in the current literature of any study that has evaluated the EASIX score in severe infection s in newly diagnosed AML patients that undergo intensive chemotherapy. OBJECTIVES Main objective is to a nalyze if EASIX i s a predictor of severe infectious complications in newly diagnosed AML patients that undergo intensive chemotherapy. Secondary objectives are to determine whether EASIX associates with treatment related mortality in 28 days CR and/or CRI. DESIGN AND METHODS : A prospective multicenter cohort study will be conducted within the CETLAM group. Each hospital will have a hematologist that will participate in patient recruitment, data collection and database input. Descriptive, bivariate and multivariate analysis are performed. PARTICIPANTS : Patients with newly diagnosed of AML that have not started treatment yet